Publications by authors named "S Royal"
Chytridiomycosis in a colony of hellbenders Cryptobranchus alleganiensis.
J Aquat Anim Health
December 2024
Article Synopsis
- The eastern hellbender salamander is endangered and suffers from chytridiomycosis, a fungal disease primarily caused by Batrachochytrium dendrobatidis (Bd), leading to symptoms like skin shedding and death.
- At Purdue University, 33% of hellbenders experienced mortality; autopsies revealed chytridiomycosis and a co-infection with Aeromonas hydrophila.
- The outbreak was attributed to environmental stress from filtration failure; after treatment, surviving salamanders have remained healthy for over a year and were released back into the wild.
Dynamically unstable polymers capture and move cellular cargos in bacteria and eukaryotes, but regulation of their assembly remains poorly understood. Here we describe polymerization of Alp7A, a bacterial actin-like protein (ALP) that distributes copies of plasmid pLS20 among daughter cells in . Purified ATP-Alp7A forms dynamically unstable polymers with a high critical concentration for net assembly (cc = 10.
View Article and Find Full Text PDFObjectives: About 60% of antibiotic prescribing in primary care is for respiratory tract infections (RTIs), some of which is likely unnecessary. There is limited evidence on the association between reduced antibiotic prescribing and adverse events. We aimed to identify associations between practice-level prescribing rates for RTIs in general practice, and patient-level adverse outcomes.
View Article and Find Full Text PDFMore patients are seen in primary care than in any other part of the health system in the UK. Our NHS datasets are the envy of the world and provide us with huge opportunities to support our patients and populations. In this paper, we demonstrate the breadth of primary care research, recruitment and delivery options.
View Article and Find Full Text PDFArticle Synopsis
- - A study was conducted to evaluate the safety and effectiveness of nirsevimab, a monoclonal antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV) in healthy infants during their first RSV season.
- - Infants aged 12 months or younger who were born at least 29 weeks gestation were randomly assigned to receive either nirsevimab or standard care, with results showing that 0.3% in the nirsevimab group were hospitalized compared to 1.5% in the standard-care group, indicating an 83.2% efficacy for nirsevimab.
- - The study also found that severe cases of RSV were less common in the nirsevimab